Jazz Calls Down Series B

Jazz Pharmaceuticals Inc. of Palo Alto, Calif. has completed the tranched calldown of a $250 million Series B round it first announced in early 2004. Participants included KKR, Prospect Venture Partners, Versant Ventures, Beecken Petty O'Keefe & Co., Golden Gate Capital and Thoma Cressey Equity Partners, Adams Street Partners, EGS Healthcare Capital Partners, Lehman Brothers Healthcare Fund and Oak Hill Capital. www.orphan.com